絞り込み

17057

広告

A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.

著者 Jones RL , Chawla SP , Attia S , Schöffski P , Gelderblom H , Chmielowski B , Le Cesne A , Van Tine BA , Trent JC , Patel S , Wagner AJ , Chugh R , Heyburn JW , Weil SC , Wang W , Viele K , Maki RG
Cancer.2019 Apr 29 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (8view , 0users)

Full Text Sources

Medical

Miscellaneous

Ontuxizumab, a humanized monoclonal antibody, targets endosialin (tumor endothelial marker 1 [TEM-1] or CD248), which is expressed on sarcoma cells and is believed to be involved in tumor angiogenesis. This is the first trial to evaluate ontuxizumab in patients with sarcoma.
PMID: 31034598 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード